Welcome to Paras Biopharmaceuticals Finland Oy

Paras Biopharmaceuticals Finland Oy is a Finnish biopharmaceuticals company started in 2012. Comprising of protein scientists, bioprocess engineers and technologists, Paras Biopharmaceuticals’ team has strong experience in developing biologics in a most efficient manner.

Company main activities & offerings are in 3 major areas:

Contract development & microbial biologics manufacturing (CDMO) – Company offers small scale (10L), medium sale (150L) & large scale (750L or more) production services.

Development & Licensing of Biosimilars – Paras Biopharmaceuticals has developed and is now offering the following Biosimilars: Recombinant Teriparatide (Forteo Biosimilar), Recombinant Anakinra (Kineret Biosimilar), Analog Insulin Aspart and Recombinant Romiplostim (N-plate Biosimilar). Further Biosimilars are in the pipeline. Due to its own developed technologies, the company has achieved efficient and cost effective production of some high value biosimilars. This is based on Paras Biopharmaceuticals’ proprietary platform which includes Diabrid® Technology, Noblecleav® Technology and Biomultifold® Technology.

Recombinant Bioprocess Enzymes – Paras Biopharmaceuticals has developed and is offering Recombinant Bioprocess enzymes. These include Recombinant Enterokinase (RapidEK®) & Tev Protease (RapidTEV®) which are used in the cleavage of fusion proteins. Paras Biopharmaceuticals is ready to cater to biopharma needs for scale-up / commercial scale production.


Biomultifold® Microbial Expression Technology

Biomultifold® provides an innovative and highly efficient process for the production of recombinant proteins using an E. Coli expression system. Biomultifold® enables to achieve expression levels of multigrams of therapeutic proteins per liter of fermentation.

Paras NobleCleav® Technology

NobleCleav® is a proprietary technology for efficient processing of recombinant therapeutic peptides and therapeutic proteins. The technology facilitates high level production of authentic biologics by combining high specificity and activity of processing.

Key Highlights of our Core Strengths

 

Innovators of Diabrid NobleCleav® Technology...

Diabrid® Technology is a unique proprietary technology for the expression of recombinant therapeutic proteins and therapeutic peptides. The technology facilitates a higher expression of therapeutic proteins in a manner that enhances the quality and bio effectiveness of the molecules in addition to facilitating post production protocols.

Paras Biopharmaceuticals Finland Oy

Paras Biopharmaceuticals Finland Oy is an up-and-coming biopharmaceutical technology development company which has successfully developed the Diabrid Platform Technology proprietary for the high level expression of biosimilars in specially designed genetically stable clones.

Business and R&D Team


Company Presentation 2018

Company Presentation 2016

Company Presentation 2014

Company Presentation 2012

Latest News

Meet Us At

Technology

Paras Biopharmaceuticals Finland Oy offers a wide spectrum of biopharmaceuticals technologies for therapeutic peptides, proteins and process technologies.

Paras Biopharmaceuticals Finland Oy Offers

Diabrid® Technology
NobleCleav® Technology
Biomultifold® Technology
Oxidative Proteinfolding Technology

Photo Gallery

Connect with us

Paras Biopharmaceuticals
Finland Oy
,

Kiviharjunlenkki 10, OULU,
FI-90220 Finland

P: +358 442709462

Dr Ashesh Kumar
E: kumar.ashesh@parasbiopharma.com
P: +358 (0) 400207380

Dr Upendra Khurana
E: upendra.khurana@parasbiopharma.com
P:+358 (0) 449783160

Dr Mark Jackson
E: mark.jackson@parasbiopharma.com
P:+358 (0) 442905993

Skype: Paras.Finland